Bicycle Therapeutics (BCYC) Expected to Post Quarterly Earnings on Friday

Bicycle Therapeutics (NASDAQ:BCYC) is expected to be posting its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Bicycle Therapeutics to post earnings of ($0.5756) per share and revenue of $4.2210 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The business had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $4.22 million. On average, analysts expect Bicycle Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicycle Therapeutics Trading Up 0.8%

BCYC stock opened at $3.97 on Thursday. The firm has a 50 day simple moving average of $4.15 and a 200-day simple moving average of $4.86. The company has a market capitalization of $277.15 million, a P/E ratio of -1.45 and a beta of 1.55. Bicycle Therapeutics has a twelve month low of $3.74 and a twelve month high of $9.16.

Analyst Ratings Changes

A number of research analysts have commented on BCYC shares. Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley cut their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $12.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.86.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer owned 605,408 shares in the company, valued at $2,585,092.16. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,977 shares of company stock valued at $42,702 over the last three months. Insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently modified their holdings of the business. Invesco Ltd. acquired a new stake in Bicycle Therapeutics during the fourth quarter worth about $71,000. State of Tennessee Department of Treasury boosted its stake in Bicycle Therapeutics by 36.4% in the fourth quarter. State of Tennessee Department of Treasury now owns 61,153 shares of the company’s stock valued at $433,000 after acquiring an additional 16,311 shares during the period. XTX Topco Ltd grew its holdings in shares of Bicycle Therapeutics by 309.3% during the fourth quarter. XTX Topco Ltd now owns 47,674 shares of the company’s stock valued at $338,000 after purchasing an additional 36,026 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of Bicycle Therapeutics by 172.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 35,709 shares of the company’s stock valued at $253,000 after purchasing an additional 22,615 shares during the last quarter. Finally, Quadrature Capital Ltd raised its position in shares of Bicycle Therapeutics by 67.5% during the 4th quarter. Quadrature Capital Ltd now owns 46,728 shares of the company’s stock worth $331,000 after purchasing an additional 18,834 shares during the period. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.